Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 191

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 191
---
 programs; •The combination with Aptorum Group will allow DiamiR to grow as part of a global company with broader network of experts and key opinion leaders; •Business combination with a publicly listed company is expected to provide DiamiR with access to additional resources, including capital, to advance its product candidates for brain health, cancer and inflammatory diseases and to create value to shareholders; •DiamiR’s lead program is focused on detecting, monitoring, and predicting risk of progression of brain health indications, such as mild cognitive impairment and Alzheimer’s disease; there is a huge need in these testing solutions and a public company platform is better suited for this objective. After giving consideration to these and other factors (including such factors as mentioned above for Aptorum’s reasoning for entering the merger), DiamiR’s board of directors approved the Merger, which the DiamiR board of directors believes better positions DiamiR for long -termsuccess. Valuation of DiamiR and Merger Consideration Between April and May 2025, an estimated preliminary conversion ratio was determined by senior management and the Board of Directors of Aptorum and DiamiR in direct discussions based on available quantitative and qualitative information regarding each of the companies, as well as the experience and judgement of management and the board of directors for each company. Management and the Board of Directors of Aptorum and DiamiR considered the following factors, among others: •The quoted market price of Aptorum Class A ordinary shares •The nature of and value ascribed to prior transactions involving the issuance by DiamiR of its common stock •Aptorum’s and DiamiR’s recent financing activities •Other publicly available information of Aptorum 97 •The markets for DiamiR’s tests in development and their stage of development •The intellectual property and human and financial resources of each •Available information regarding Aptorum’s and DiamiR’s future plans •Observable valuations and transactions of similar companies •Anticipated risk factors Between May12, 2025 and July13, 2025, Aptorum and DiamiR, and their respective legal counsels, generally exchanged further internal information, including working capital needs, and conducted customary due diligence. The companies developed and reviewed further information regarding the valuation of comparable companies. On July7, 2025, DiamiR entered into a financial advisory agreement with H.C. Wainwright & Co., LLC (“Wainwright”), with Wainwright to act as exclusive financial advisor to DiamiR in connection with the Merger.